Login to Your Account

Kolon Life Science's Invossa receives approval amid efficacy skepticism

By Haky Moon
Staff Writer

Monday, July 17, 2017

HONG KONG – After more than a decade of development, Maryland-based Tissuegene Inc. and its Asia licensee, Kolon Life Science Inc., received a bittersweet go-ahead from the South Korean authorities to market gene therapy drug Invossa-K.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription